Q&A: New BIO chair to steer industry through ‘existential threats’ despite FDA receptivity

Max Bayer

Pharma Reporter

BOSTON — Fritz Bittenbender, the newly-named chair of BIO, is guiding the group through the kind of split-screen experience that has defined the first several …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Q&A: New BIO chair to steer industry through ‘existential threats’ despite FDA receptivity

Max Bayer

Pharma Reporter

Sign up to read this article for free.

How a tailored ALS drug could help broaden rare disease therapies

Gilead gets groundbreaking FDA approval for twice-yearly HIV prevention shot

Grail shares jump on study results for cancer test

Scholar Rock’s muscle-preserving obesity drug add-on looks competitive

Zealand study shows higher GLP-1/GLP-2 doses may lead to greater weight loss

This company has spent a decade innovating NGS-based companion diagnostics worldwide–what’s next?

Q&A: New BIO chair to steer in­dus­try through ‘ex­is­ten­tial threats’ de­spite FDA re­cep­tiv­i­ty

Max Bayer

Pharma Reporter

Sign up to read this article for free.

How a tai­lored ALS drug could help broad­en rare dis­ease ther­a­pies

Gilead gets ground­break­ing FDA ap­proval for twice-year­ly HIV pre­ven­tion shot

Grail shares jump on study re­sults for can­cer test

Schol­ar Rock’s mus­cle-pre­serv­ing obe­si­ty drug add-on looks com­pet­i­tive

Zealand study shows high­er GLP-1/GLP-2 dos­es may lead to greater weight loss

This com­pa­ny has spent a decade in­no­vat­ing NGS-based com­pan­ion di­ag­nos­tics world­wide–what’s next?

Q&A: New BIO chair to steer industry through ‘existential threats’ despite FDA receptivity

How a tailored ALS drug could help broaden rare disease therapies

Gilead gets groundbreaking FDA approval for twice-yearly HIV prevention shot

Grail shares jump on study results for cancer test

Scholar Rock’s muscle-preserving obesity drug add-on looks competitive

Zealand study shows higher GLP-1/GLP-2 doses may lead to greater weight loss

This company has spent a decade innovating NGS-based companion diagnostics worldwide–what’s next?